Image 1_Quality of life in patients with pan-cancer undergoing concurrent chemoradiotherapy: a bibliometric analysis (1995-2024).tif by Ao Shen (127290)

“…Background<p>Chemoradiotherapy is a therapeutic approach that prolongs survival but may simultaneously negatively affect the quality of life (QOL) of cancer patients. …”

Table 1_Quality of life in patients with pan-cancer undergoing concurrent chemoradiotherapy: a bibliometric analysis (1995-2024).docx by Ao Shen (127290)

“…Background<p>Chemoradiotherapy is a therapeutic approach that prolongs survival but may simultaneously negatively affect the quality of life (QOL) of cancer patients. …”

Data_Sheet_1_A Non-linear Relationship Between Selective Attention and Associated ERP Markers Across the Lifespan.docx by Eva-Maria Reuter (6268742)

“…<p>The ability to selectively attend to task-relevant information increases throughout childhood and decreases in older age. Here, we intended to investigate these opposing developmental trajectories, to assess whether gains and losses early and late in life are associated with similar or different electrophysiological changes, and to get a better understanding about the development in middle-adulthood. …”

Data_Sheet_1_Predicting potential distributions of Monochamus saltuarius, a novel insect vector of pine wilt disease in China.docx by Ruihe Gao (16970337)

“…Using future climatic scenarios SSP126 and SSP585, the predicted suitable areas of M. saltuarius will continue to expand from that of 2040, 2070, and 2100, with highly and moderately suitable areas showing larger increasing trends but low suitable distribution areas will decrease to varying degrees. …”

The SOS Response Master Regulator LexA Is Associated with Sporulation, Motility and Biofilm Formation in <i>Clostridium difficile</i> by Beata M. Walter (839026)

“…Here we describe the construction and characterization of a <i>lexA</i> ClosTron mutant in <i>C</i>. …”

Table_2_Metabolic Perturbations Caused by the Over-Expression of mcr-1 in Escherichia coli.docx by Yi-Yun Liu (3157737)

“…In contrast, levels of intermediate metabolites of peptides, amino sugars, carbohydrates and nucleotide metabolism and secondary metabolites significantly decreased. Moreover, the over-expression of mcr-1 resulted in a prolonged reduction in intermediates associated with pentose phosphate pathway and pantothenate and CoA biosynthesis. …”

Table_1_Metabolic Perturbations Caused by the Over-Expression of mcr-1 in Escherichia coli.docx by Yi-Yun Liu (3157737)

“…In contrast, levels of intermediate metabolites of peptides, amino sugars, carbohydrates and nucleotide metabolism and secondary metabolites significantly decreased. Moreover, the over-expression of mcr-1 resulted in a prolonged reduction in intermediates associated with pentose phosphate pathway and pantothenate and CoA biosynthesis. …”

Table_3_Metabolic Perturbations Caused by the Over-Expression of mcr-1 in Escherichia coli.docx by Yi-Yun Liu (3157737)

“…In contrast, levels of intermediate metabolites of peptides, amino sugars, carbohydrates and nucleotide metabolism and secondary metabolites significantly decreased. Moreover, the over-expression of mcr-1 resulted in a prolonged reduction in intermediates associated with pentose phosphate pathway and pantothenate and CoA biosynthesis. …”

Data_Sheet_1_Metabolic Perturbations Caused by the Over-Expression of mcr-1 in Escherichia coli.xlsx by Yi-Yun Liu (3157737)

“…In contrast, levels of intermediate metabolites of peptides, amino sugars, carbohydrates and nucleotide metabolism and secondary metabolites significantly decreased. Moreover, the over-expression of mcr-1 resulted in a prolonged reduction in intermediates associated with pentose phosphate pathway and pantothenate and CoA biosynthesis. …”

Image_1_Metabolic Perturbations Caused by the Over-Expression of mcr-1 in Escherichia coli.pdf by Yi-Yun Liu (3157737)

“…In contrast, levels of intermediate metabolites of peptides, amino sugars, carbohydrates and nucleotide metabolism and secondary metabolites significantly decreased. Moreover, the over-expression of mcr-1 resulted in a prolonged reduction in intermediates associated with pentose phosphate pathway and pantothenate and CoA biosynthesis. …”

Image_1_Interleukin-37 Ameliorates Influenza Pneumonia by Attenuating Macrophage Cytokine Production in a MAPK-Dependent Manner.TIF by Feifei Qi (3070155)

“…Interleukin-37 (IL-37) has been reported to inhibit excessive immune responses and protect against a variety of inflammatory diseases. In this study, by using BALB/c mice intranasally infected with A/California/07/2009 (H1N1), we found that IL-37 treatment increases the survival rate and body weight, and reduces the pulmonary index, impaired the lung injury and decreased production of pro-inflammatory cytokines in the BALF and lung tissue. …”

Data Sheet 1_Reassessing L2 sensitivity to island constraints: asymmetries between wh-islands and adjunct-islands.zip by Boyoung Kim (756641)

“…The overall magnitude of island effects was smaller in L2 speakers and decreased systematically with later Age of Arrival (AoA). …”

Increasing Nucleosome Occupancy Is Correlated with an Increasing Mutation Rate so Long as DNA Repair Machinery Is Intact by Puya G. Yazdi (725739)

“…Recently, chromatin has been shown to play a part in this process. To elucidate this relationship further, we integrated our own ultra-deep sequenced human nucleosomal DNA data set with a host of published human genomic and cancer genomic data sets. …”

Data Sheet 7_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…Introduction<p>Chemoresistance and disease relapses in epithelial ovarian cancer (EOC) highlight the need for novel therapeutic strategies. Here, we investigated phosphodiesterase 7A (PDE7A) as a potential target in ovarian cancer treatment.…”

Data Sheet 6_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…Introduction<p>Chemoresistance and disease relapses in epithelial ovarian cancer (EOC) highlight the need for novel therapeutic strategies. Here, we investigated phosphodiesterase 7A (PDE7A) as a potential target in ovarian cancer treatment.…”

Data Sheet 1_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…Introduction<p>Chemoresistance and disease relapses in epithelial ovarian cancer (EOC) highlight the need for novel therapeutic strategies. Here, we investigated phosphodiesterase 7A (PDE7A) as a potential target in ovarian cancer treatment.…”

Data Sheet 3_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…Introduction<p>Chemoresistance and disease relapses in epithelial ovarian cancer (EOC) highlight the need for novel therapeutic strategies. Here, we investigated phosphodiesterase 7A (PDE7A) as a potential target in ovarian cancer treatment.…”

Data Sheet 8_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…Introduction<p>Chemoresistance and disease relapses in epithelial ovarian cancer (EOC) highlight the need for novel therapeutic strategies. Here, we investigated phosphodiesterase 7A (PDE7A) as a potential target in ovarian cancer treatment.…”

Data Sheet 4_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…Introduction<p>Chemoresistance and disease relapses in epithelial ovarian cancer (EOC) highlight the need for novel therapeutic strategies. Here, we investigated phosphodiesterase 7A (PDE7A) as a potential target in ovarian cancer treatment.…”

Data Sheet 5_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…Introduction<p>Chemoresistance and disease relapses in epithelial ovarian cancer (EOC) highlight the need for novel therapeutic strategies. Here, we investigated phosphodiesterase 7A (PDE7A) as a potential target in ovarian cancer treatment.…”